Drug Profile
Voriconazole - Pfizer
Alternative Names: Betadex sulfobutyl ether sodium enabled IV voriconazole; Captisol-enabled IV voraconazole; SBECD enabled IV voriconazole; Sulphobutly ether beta cyclodextrin enabled IV voriconazole; UK-109496; VfendLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Ligand Pharmaceuticals; Pfizer
- Class Antifungals; Fluorinated hydrocarbons; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Candidiasis; Fusariosis; Invasive bronchopulmonary aspergillosis; Mycoses
Most Recent Events
- 02 Feb 2021 Launched for Mycoses in China (IV) before February 2021 (Ligand Pharmaceuticals pipeline, Feb 2021)
- 02 Feb 2021 Launched for Mycoses in China (PO) before February 2021 (Ligand Pharmaceuticals pipeline, Feb 2021)
- 07 Aug 2018 Registered for Mycoses in China (IV)